CALENDAR OF EVENTS
NEXT EVENT:
|
Date:
Thursday, February 25, 2010 |
Time:
7:00 am |
Open To:
Members & Non-Members |
| More Info > |
|
|
Funding Life Sciences: Where to Now?
Thurs. Feb 25, 7:00-9:00am - Hyatt Regency La Jolla
Sponsored by Mayer Hoffman McCann, Luce Forward and Cabrillo Advisors
The environment for traditional means of funding private companies in the life science industry has changed forever. No longer are venture capitalists the logical choice for funding companies with pre-clinical programs. By the same token, using vast amounts of cash to advance these programs is no longer condoned.
Companies who are successful in raising capital need to be extremely efficient and manage their limited cash resources to ensure that they achieve their milestones in a manner that is faster, better and cheaper.
Join us on Thursday, February 25 as our panel of experienced investors explores how companies in the life science industry can seek to accomplish their goals with -- or without -- traditional funding from venture capitalists. The speakers will address their funding strategies, as well as how companies today are utilizing resources that are much more efficient and cost effective.
Don’t miss this program. Please join us for a look into the future of successful investment in biotech!
Confirmed Panelists:
Scott Salka (moderator) - CEO, Ambit Biosciences
Scott's expertise was earned at the helm of several genomics companies. Prior to joining Ambit in 2001, he served as the President and CEO of two privately-held genomics companies, Arcaris, Inc. and 454 Corporation. He also previously co-founded one of the first commercial genomics companies, Sequana Therapeutics, Inc., a pioneer in the effort to commercialize the international Human Genome Project.
Cam Gallagher - President and CEO, Nerveda
Cam is the President and Chief Executive Officer of Nerveda, a privately funded life science organization dedicated to advancing novel therapeutic and diagnostic technologies for neurodegenerative diseases. Prior to Nerveda, he was Vice President, Marketing of Verus Pharmaceuticals, a pediatric oriented company focused on improving the health and wellness of children. From 1992 to 2004 he held a variety of positions within commercial operations with increasing levels of responsibility at Dura Pharmaceuticals and CV Therapeutics. Cam is a co-founder and has served as chairman of the DioGenix board since the company was founded in September 2008.
Jay Lichter - Managing Director, Avalon Ventures
Jay is a biotechnology and pharmaceutical business executive with over 20 years experience in management, scientific research and business development who has participated in licensing or M&A deals valued in excess of $1 billion. Until November 2008, Dr. Lichter served as President and CEO of Akesis Pharmaceuticals, a developer of patent protected diabetes drugs. In 2004, Dr. Lichter co-founded Sytera, Inc., an ophthalmic-focused biopharmaceutical company which was acquired by Sirion Therapeutics, Inc. Early in his career, Dr. Lichter was a co-founder of Sequana Therapeutics, a genomics-base drug discovery company, and in 2000 he co-founded and was CEO of Xenopharm, a drug safety company. He has served in management positions at Sequenom, Pfizer and Genset.
Nikolay Savchuk - Director, Torry Pines Investment Inc.
Torrey Pines Investments has created biopharma incubators investing in early development stage assets from international pharma and biotech partners in CNS, oncology, and virology area to bring them to commercial success through pharma partnering and M&A. Nikolay is also President and CEO of ChemDiv, Inc. (San Diego CA), Chairman of Viriom Ltd and Chemical Diversity Research Institute in Moscow Russia, and serves on the board of ChemRar Hi Tech Center (Moscow, Russia). He has led the ChemDiv's business team since 1998. He is a founder of the Inel Group of IT and media companies in Singapore and Russia, and was an industry representative to the Russian government's Pharma 2020 initiative.
|
ABOUT OUR MEETINGS
The SDVG hosts eleven meetings each year, approximately one per month. Programs typically feature a panel discussion by cross-industry experts on a specific entrepreneurial or venture capital-related topic.
Please make note of the upcoming dates for San Diego Venture Group meetings, as listed on our home page (www.sdvg.org -- scroll down to "Upcoming SDVG Events"). Unless specified otherwise, the meetings are held at the Hyatt Regency in La Jolla from 7:00 - 9:00 a.m.
The non-member fee for most breakfast meeting is $45 with advance reservations ($55 at the door). SDVG members attend our standard breakfast events at no cost and receive deeply discounted rates on our "premium" events.
____________________________________________________________________
